Pancreas adenocarcinoma: novel therapeutics
Benjamin A. Krantz, Kenneth H. Yu, Eileen M. O’Reilly.
Chinese Clinical Oncology. 2017.
“Targeting RAS by inhibiting
translation using small-interfering RNAs is a novel strategy
to decrease RAS activity. siRNA against the G12D mutant
RAS RNA by local prolonged delivery, siG12D LODER
(Local Drug EluteR), has demonstrated decreased growth of
human pancreatic tumor cells in vivo and prolonged mouse
survival. In a phase Ib/II dose escalation 15 locally
advanced, unresectable patients received siG12D LODER
with a mOS of 15.12 months. Ten out of 12 patients
had SD on repeat imaging and 2 had a PR.”